FOLH1 and prostate carcinoma: PSMA PET/CT seeks to improve on conventional diagnostic tests and imaging in the special subset of patients that have already had a negative prostate biopsy and, at times, a negative mpMRI and who continue to have a high clinical suspicion of prostate cancer.